Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Non-group M HIV-1 (O, N, and P) are known as genetically divergent and mainly found in Cameroon. Due to the prevalent Y181C mutation in 75% of non-M strains, current treatment guidelines has not recommended the use of Non-Nucleoside Reverse Transcriptase Inhibitors. However, the specific resistance profile of Doravirine (DOR) challenges this recommendation. The DORAVI-O…
Background Despite significant progress made in antiretroviral (ARV) therapy for human immunodeficiency virus-1 (HIV-1) treatment, one of the major challenges facing the efficacy of ARV is drug resistance. The objective of this study was to evaluate clinical outcomes associated with resistance to ARV among people with HIV (PWH). Methods This national retrospective cohort study was…
Background In general population adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and non-cirrhotic liver fibrosis, the glucagon-like peptide-1 receptor agonist semaglutide (SEMA) improves steatohepatitis (MASH) but not liver fibrosis. The OWLiver metabolomics algorithm is validated against liver biopsy in general population cohorts and uses serum profiling to distinguish MASLD from No MASLD. Among persons…
Background Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in experienced patients in Mexico, where Efavirenz (EFV) was the preferred initial ARV drug for more than 10 years. Methods Genotypic sequence data from 2442 patients experiencing…
Background Steatotic liver disease (SLD) is a common condition in PLWH, linked to overweight and associated metabolic disorders. Both INSTIs and TAF have been associated with weight gain in clinical trials and real-life studies. Likewise, TAF has also been associated with SLD. Controversial results have been reported regarding INSTIs and SLD. In virologically suppressed PLWH,…
Background Second-generation integrase inhibitors are the cornerstone of antiretroviral therapy (ART) worldwide. Recently, WHO reported higher levels of dolutegravir (DTG) resistance in some low and middle-income countries compared to clinical trial data. As resources for resistance testing remain limited, we implemented a prospective reflex testing strategy (ITREMA-2) to prioritize resistance testing to those most likely…
Background The isolated anti-core pattern (antiHBc+, antiHBs-, HBsAg-) is more frequently observed in people living with HIV (PWH). It suggests a past hepatitis B virus (HBV) infection; however, it can also indicate an occult HBV infection, which implicates a risk of viral reactivation. Historically, antiretroviral (ART) regimens containing tenofovir (TXF) have effectively suppressed HBV replication,…
Background Integrase strand transfer inhibitors (INSTIs) are the cornerstone of current HIV therapies, but their oral dosing remains limited to once-daily administration. Herein we describe the in vitro resistance profile for GS-1720, a potent and selective investigational INSTI with Phase 1 clinical pharmacokinetic, safety and antiviral efficacy data supportive of once-weekly oral dosing. Methods GS-1720…
Background The clinical consequences of a low-level viremia (LLV) result (HIV-1 RNA 50-999 copies/mL) after a high viral load (VL) result (≥1,000 copies/mL) and intensive adherence counseling (IAC) are uncertain. The probability of future virological failure may be determined by the presence of drug resistance mutations (DRMs), but WHO does not recommend HIV drug resistance…
Background Lenacapavir (LEN) is an FDA-approved drug for highly treatment-experienced individuals living with multidrug-resistant HIV-1 infection. LEN inhibits HIV-1 replication with sub-nanomolar potency by targeting the capsid protein (CA) at the “FG-binding pocket” (FGBP). Clinical trials report the emergence of CA mutations like M66I and N74D after LEN treatment. N74D is also selected by PF74,…